Antibe Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATBPF research report →
About the company
Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine.
- CEO
- Daniel Marcel Legault
- IPO
- 2014
- Employees
- 11
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $11.43M
- P/E
- -0.79
- P/S
- 0.00
- P/B
- 0.38
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -40.16%
- ROIC
- -28.48%
- Revenue
- $0 · 0.00%
- Net Income
- $-19,475,000 · 22.29%
- EPS
- $-0.37 · 24.49%
- Op Income
- $-20,546,000
- FCF YoY
- 3.63%
- 52W High
- $0.22
- 52W Low
- $0.19
- 50D MA
- $0.22
- 200D MA
- $0.22
- Beta
- 0.58
- Avg Volume
- 9.61K
Get TickerSpark's AI analysis on ATBPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ATBPF coverage
Recent articles, reports, and earnings notes.
No research on ATBPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATBPF report →Similar companies
Peers in the same neighborhood.